ClinicalTrials.gg
TerminatedNCT06028230ZENUpdated Dec 11, 2025

A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 2 interventional study of SAR444656 (KT-474) and Placebo in Hidradenitis Suppurativa, sponsored by Sanofi. Terminated at 52 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor decision. Not related to safety concern.

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Hidradenitis Suppurativa with a site in United States — 39 open to participants now, 56 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.

Enrollment
62nd of 139
70 · median 45
Started
2023
with 12 others
Phase 2
61 of 162
11 open now
Registered
106th of 162
by date

Among the 162 studies in Hidradenitis Suppurativa with a site in United States, this one is the 62nd largest by enrollment of the 139 interventional ones that give a count, is one of 13 that started in 2023, is one of 61 in phase 2, and was the 106th registered.

Hidradenitis Suppurativa

286 studies on the registry are indexed under Hidradenitis Suppurativa; 89 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

39 of the 162 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 63 Hidradenitis Suppurativa studies recruiting now, 35 (56%) set no upper age limit and 17 (27%) stop at 75 or younger; 13 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Hidradenitis Suppurativa with a site in United States, or all of them as a file.
02

Study summary

This is a parallel, Phase 2, 3-arm study to evaluate the efficacy, safety, PK, and biological effects of SAR444656 compared with placebo in adult participants with moderate to severe HS aged ≥18 to 70 years.

Study details include:

  • Screening period: up to 4 weeks (30 days)
  • Treatment duration: up to 16 weeks
  • Follow-up period: up to 4 weeks
  • Total study duration: up to 24 weeks
  • Number of visits: 14
03

Conditions studied

  • Hidradenitis Suppurativa
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant with a history of signs and symptoms consistent with HS for at least 1 year prior to baseline.
  • Participant must have HS lesions present in at least 2 distinct anatomic areas, one of which must be Hurley Stage II or Hurley Stage III.
  • Participant must have had an inadequate response after at least one-month of oral antibiotic treatment for HS, as assessed by the Investigator.
  • Participant must have a total AN count of ≥5 at the baseline visit.
  • Participant must have a draining tunnel count of ≤20 at the baseline visit.
  • Participant must be willing and able to complete the diary for the duration of the study as required by the study protocol.
  • use by men with a partner of and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • Participant with any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with assessment of HS.
  • Any active or chronic infection requiring systemic treatment (eg, antibiotics, antivirals, antifungals, antihelminthics) within 30 days prior to baseline.
  • Known history of or suspected significant suppressed immune response, including history of invasive opportunistic or helminthic infections despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged duration.
  • Participant with history of solid organ transplant.
  • Participant with history of splenectomy.
  • Participant with history of any or lymphoproliferative disease, except if the participant has been free from disease for ≥5 years. Successfully treated non- cutaneous squamous cell carcinoma, basal cell carcinoma, or localized carcinoma in situ of the cervix are allowed.
  • Participant with a diagnosis of chronic immune-mediated, inflammatory conditions other than HS
  • Participant with family history of sudden death or long syndrome.
  • Participant with history of congenital or drug-induced long QT syndrome.
  • Participant with congestive heart failure ( Class 2 to 4), greater than Class 1 angina pectoris, acute coronary syndrome within prior 6 months, known structural heart disease.
  • Participant with history of any major cardiovascular events (eg, myocardial infarction, unstable angina pectoris, coronary revascularization, stroke, or ) at any time prior to screening.
  • Participant with history of ventricular fibrillation, ventricular tachycardia, torsades de pointes, atrial fibrillation, syncope not explained by non-cardiac etiology.
  • Participant with uncontrolled hypertension defined as consistent systolic blood pressure ≥150 mmHg or consistent diastolic blood pressure ≥90 mmHg despite antihypertensive medication.
  • Participant received prescription topical therapies for the treatment of HS within 14 days prior to the baseline visit.
  • Prior or active treatment with any systemic biologic (anti-TNF) therapy, anti-IL17 therapy, anti-IL1/anti-IL1 receptor therapy except for up to 20% of the total study population. Furthermore, this 20% of biologic-experienced participants must fulfilled one or more of the following conditions:

    • Discontinued due to treatment related toxicity and/or
    • Discontinuation is not related to lack or loss of therapeutic response.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    SAR444656 dose 1

    Participants will receive SAR444656 dose 1 orally

    Drug: SAR444656 (KT-474)

  • Experimental
    SAR444656 dose 2

    Participants will receive SAR444656 dose 2 orally

    Drug: SAR444656 (KT-474)

  • Placebo comparator
    Placebo

    Participants will receive placebo orally

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in total abscess and inflammatory nodule (AN) count

    The AN count is the sum of the abscess count and inflammatory nodule count at any given clinical assessment. It is derived from the lesion counts obtained as part of the HS clinical parameters.

    Time frame: Week 16

Secondary outcomes

  1. Proportion of participants achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR 50)

    Time frame: Week 16

  2. Proportion of participants achieving AN count ≤2

    Time frame: Week 16

  3. Absolute change from baseline in International Hidradenitis Suppurativa Severity Score System (IHS4)

    Time frame: Week 16

  4. Proportion of participants with improvement from baseline in Hurley Stage

    Time frame: Week 16

  5. Proportion of participants achieving AN50 (at least 50% reduction in the AN count relative to baseline)

    Time frame: Week 16

  6. Change from baseline in participants reported daily worst pain using HS-Skin Pain-Numerical Rating Scale (HS-Skin Pain-NRS)

    Time frame: Week 16

  7. Proportion of participants achieving improvement defined as at least 30% reduction and at least 1 unit reduction in participant daily worst pain using HS-Skin pain-NRS

    Time frame: Week 16

  8. Change from baseline in the amount of analgesic

    Time frame: Up to Week 16

  9. Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs), investigational medicinal product (IMP) discontinuation due to TEAEs

    Time frame: Up to Week 20

  10. Plasma SAR444656 concentration

    Time frame: Up to Week 16

07

Study locations

52 sites
  • Clear Dermatology & Aesthetics Center- Site Number : 8400006
    Scottsdale, Arizona 85255, United States
  • Cosmetic Dermatology of Orange County- Site Number : 8400024
    Anaheim, California 92807, United States
  • First OC Dermatology - Fountain Valley- Site Number : 8400007
    Fountain Valley, California 92708-3701, United States
  • Paradigm Clinical Research - San Diego - ClinEdge - PPDS- Site Number : 8400021
    San Diego, California 92108, United States
  • Clinical Trials Management Services - Thousand Oaks- Site Number : 8400028
    Thousand Oaks, California 91360, United States
  • Advanced Dermatology and Cosmetic Care- Site Number : 8400025
    Valencia, California 91355, United States
  • Encore Medical Research of Boynton Beach- Site Number : 8400002
    Boynton Beach, Florida 33436, United States
  • Moore Clinical Research - Brandon- Site Number : 8400001
    Brandon, Florida 33511, United States
  • Encore Medical Research - 6600 Taft St- Site Number : 8400005
    Hollywood, Florida 33024, United States
  • Sullivan Dermatology- Site Number : 8400003
    Miami, Florida 33162, United States
  • ARA Professionals- Site Number : 8400023
    Miami, Florida 33176-1032, United States
  • Encore Medical Research - Weston- Site Number : 8400010
    Weston, Florida 33331, United States
  • Dermatology Specialists Research (DS Research) - Indiana- Site Number : 8400012
    Clarksville, Indiana 47129, United States
  • Dawes Fretzin Clinical Research- Site Number : 8400011
    Indianapolis, Indiana 46256, United States
  • Beth Israel Deaconess Medical Center - 110 Francis St- Site Number : 8400013
    Boston, Massachusetts 02215-5563, United States
  • Wayne Health - Dearborn- Site Number : 8400004
    Dearborn, Michigan 48124-4085, United States
  • Revive Research Institute-1575 W Big Beaver Rd- Site Number : 8400008
    Troy, Michigan 48084-3536, United States
  • Vial Health - DermDox Dermatology- Site Number : 8400020
    Camp Hill, Pennsylvania 17011, United States
  • Clinical Research Philadelphia,LLC- Site Number : 8400026
    Philadelphia, Pennsylvania 19114-1025, United States
  • UPMC Montefiore- Site Number : 8400009
    Pittsburgh, Pennsylvania 15213, United States
  • Dermatology Specialists of Spokane- Site Number : 8400015
    Spokane, Washington 99202-1332, United States
  • Investigational Site Number : 1240004
    Québec, Quebec G1W 4R4, Canada
  • Investigational Site Number : 1520002
    Santiago, Reg Metropolitana de Santiago 7640881, Chile
  • Investigational Site Number : 1520003
    Independencia, 8380000, Chile
  • Investigational Site Number : 1520001
    Las Condes, 7580206, Chile
  • Investigational Site Number : 1520004
    Temuco, 4810345, Chile
  • Investigational Site Number : 2760002
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Investigational Site Number : 2760008
    Munich, Bavaria 80337, Germany
  • Investigational Site Number : 2760006
    Würzburg, Bavaria 97080, Germany
  • Investigational Site Number : 2760007
    Frankfurt am Main, Hesse 60590, Germany
  • Investigational Site Number : 2760001
    Bochum, North Rhine-Westphalia 44791, Germany
  • Investigational Site Number : 2760004
    Remscheid, North Rhine-Westphalia 42897, Germany
  • Investigational Site Number : 2760009
    Dessau, Saxony-Anhalt 06847, Germany
  • Investigational Site Number : 2760005
    Berlin, 10789, Germany
  • Investigational Site Number : 3000003
    Athens, Attica 12462, Greece
  • Investigational Site Number : 3000001
    Pavlos Melas, Thessaloniki 564 29, Greece
  • Investigational Site Number : 3000002
    Thessaloniki, 546 43, Greece
  • Investigational Site Number : 6160006
    Wroclaw, Lower Silesian Voivodeship 50-449, Poland
  • Investigational Site Number : 6160002
    Wroclaw, Lower Silesian Voivodeship 50-566, Poland
  • Investigational Site Number : 6160005
    Lodz, Lódzkie 90-436, Poland
  • Investigational Site Number : 6160003
    Warsaw, Masovian Voivodeship 00-874, Poland
  • Investigational Site Number : 6160007
    Katowice, Silesian Voivodeship 40-040, Poland
  • Investigational Site Number : 6160004
    Ossy, Silesian Voivodeship 42-624, Poland
  • Investigational Site Number : 4100002
    Cheonan-si, Chungcheongnam-do 330721, South Korea
  • Investigational Site Number : 4100001
    Seongnam-si, Gyeonggi-do 13496, South Korea
  • Investigational Site Number : 4100003
    Seongbuk-Gu, Seoul-teukbyeolsi 02841, South Korea
  • Investigational Site Number : 4100004
    Seoul, Seoul-teukbyeolsi 03080, South Korea
  • Investigational Site Number : 7240004
    Cadiz, Cádiz 11009, Spain
  • Investigational Site Number : 7240005
    Manises, Valencia 46940, Spain
  • Investigational Site Number : 7240003
    Alicante, 03010, Spain
  • Investigational Site Number : 7240001
    Granada, 18014, Spain
  • Investigational Site Number : 7240002
    Seville, 41009, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Oct 2025, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2023
First posted
Sep 8, 2023
StartActual
Sep 29, 2023
Primary completionActual
Oct 9, 2025
CompletionActual
Nov 12, 2025
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06028230
Lead sponsor
Sanofi
Collaborators
Kymera Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 8, 2023
Start date
Sep 29, 2023
Primary completion
Oct 9, 2025
Completion
Nov 12, 2025
Last update
Dec 11, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tipasertideg

Start the discussion